Nationwide Children’s gene therapy spinoff raises up to $105M, with option to be acquired – Columbus Business First
|
Nationwide Children's gene therapy spinoff raises up to $105M, with option to be acquired
Columbus Business First Sarepta Therapeutics Inc. is investing up to $105 million in the latest gene therapy spinoff from Nationwide Children's Hospital – and signed an option to acquire the company for an undisclosed but higher amount if clinical trial results are promising … |
